drugset / Trial / NCT07472647
SYS6090 Combination Therapy in Advanced Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multi-cohort, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of SYS6090 injection in combination with chemotherapy or chemotherapy and bevacizumab or SYS6010 (an EGFR ADC) in participants with advanced lung cancer.
Timeline
- Start
- 2026-02-28
- Primary completion
- 2029-02-28
- Completion
- 2030-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Etoposide | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pemetrexed | Small molecule | — | — |
| Subject | SYS6010 | Monoclonal antibody | — | — |
| Subject | SYS6090 | Unknown | — | — |